April 24, 2024 | Xcision Article
Missed Xcision’s webinar on how to reduce radiation toxicity by reducing the treatment to a single fraction?
In this clinical education webcast, Dr. Marco Trovò from Azienda sanitaria universitaria Friuli Centrale (ASU FC) in Udine, Italy, describes his experience using the GammaPod™ Stereotactic Radiotherapy System to treat patients with early stage breast tumors.
Breast cancer typically represents 25% or more of patient volumes in most radiation oncology clinics. GammaPod is being used to minimize radiation toxicity effects by reducing the radiotherapy treatment to only a single fraction delivered in under one hour.
Watch this on demand webinar to learn more about the advantages of GammaPod technology including:
- Single fraction safety toxicity profile
- Increasing the efficiency of radiation treatment
- Improving patient satisfaction
- Reducing wait times, and bringing down operational costs
Learn how these researchers concluded that radiotherapy with GammaPod is very safe with a low toxicity profile using these innovative techniques:
- A highly focused dose distribution with sharp dose fall-off
- Single fraction treatments completed in under one hour
- A small planning target volume margin due to stereotactic localization
- A single dose of 17.5Gy delivered safely with a very low acute toxicity profile
If providers could find a way to deliver faster, more effective radiation treatments for early-stage breast cancer patients, the positive impact to improved outcomes, increased patient satisfaction, reduced wait times, and additional operational savings will be tremendous.
Follow Xcision on LinkedIn to find out the latest GammaPod news for healthcare providers and patients around the world.